The rise of Sildenafil initially drove a period of growth for major pharmaceutical companies, nevertheless recent changes present a murky scenario for investors. Off-patent alternatives are reducing profits, and https://siobhanpmka800821.blazingblog.com/41216267/the-blue-pill-and-big-pharma-a-risky-investment